Navigation Links
Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
Date:4/14/2008

une mediated diseases.

"These data, along with the additional results reported at AACR with our other drug candidates, demonstrate the breadth of our product portfolio," said Richard A. Miller, M.D., president and CEO of Pharmacyclics.

About Pharmacyclics

Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and other serious diseases. The company is leveraging its small-molecule drug development expertise to build a pipeline in oncology and other diseases based on a wide range of targets, pathways and mechanisms. More information about the company, its technology, and products can be found at http://www.pharmacyclics.com. Pharmacyclics(R) and the "pentadentate" logo(R) are registered trademarks of Pharmacyclics, Inc.

NOTE: Other than statements of historical fact, the statements made in this press release about enrollment and future plans for our clinical trials, progress of and reports of results from preclinical and clinical studies, clinical development plans and product development and corporate partnering activities are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. The words "project," "believe," "will," "may," "continue," "plan," "expect," "intend," "anticipate," variations of such words, and similar expressions also identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. The forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements. Factors that could affect actual results include risks associated with unexpected delays in clinical trials and preclinical studies and the timing for making related regulatory filings; the fact that data from preclinical studies and Phase 1 or Phase 2 clinical
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
2. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
3. Genzyme Genetics Announces Launch of Carrier Testing and Prenatal Diagnosis for Spinal Muscular Atrophy
4. Perrigo Announces Approval for Over-the-Counter Childrens Cetirizine Oral Solution
5. Nuvelo Announces Preclinical Data for NU206 Demonstrating Potent Therapeutic Activity in Oral Mucositis Models
6. Napo Announces Successful Clinical Results in Phase 2 Study of Crofelemer in Acute Adult Infectious Diarrhea
7. Antipodean Pharmaceuticals Announces Completion of Phase 2 Study of Lead Compound MitoQ(R)
8. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007
9. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
10. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722
11. Favrille Announces Data Cutoff for Phase 3 Registration Trial of Specifid; Data Analysis and Unblinding Expected in June
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... TAMPA, Fla. , May 22, 2015 /PRNewswire-USNewswire/ ... Hospital,s Heart Institute recently traveled to ... Convergent procedure at the 2015 Heart Rhythm Society ... experts together to focus on the ideas, people ... Convergent is a hybrid, minimally invasive ...
(Date:5/22/2015)... 2015 The North American dental lasers ... estimated to reach $90.7 million by 2019, at a CAGR ... the TOC of North America Dental Lasers Market for an ... various tables and figures. http://www.micromarketmonitor.com/market/north-america-dental-lasers-1771208223.html ... report.   Dental lasers are specifically used ...
(Date:5/22/2015)... , May 22, 2015  The U.S. Food ... (filgrastim-sndz) -- the first biosimilar product approved in ... points toward growth in the contract manufacturing organization ... CMO industry is geared to the production of ... major biopharmaceutical products. The healthcare market research publisher,s ...
Breaking Medicine Technology:St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 2St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 3North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 2North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4
... , KRX-0401 + Capecitabine More Than Doubles Time ... Overall Survival vs. Capecitabine + Placebo in Patients with ... NEW YORK, June 1 Keryx Biopharmaceuticals, Inc. (Nasdaq: ... of KRX-0401 (perifosine), the Company,s Akt-inhibitor for cancer, in combination ...
... GATESHEAD, England, June 1 A leading GP has ... around the world the hope of combating the killer disease. , ... of Ateronon, the natural supplement,developed by Cambridge scientists, was a huge ... heart attacks and stroke. , Dozens of ...
Cached Medicine Technology:Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 2Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 3Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 4Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 5Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 6Heart Disease Treatment Breakthrough 2Heart Disease Treatment Breakthrough 3
(Date:5/22/2015)... San Francisco, CA (PRWEB) May 22, 2015 ... is hosting two exciting events in June. They will ... First Professional Doctorate and a two-day class on Classical ... 1:30-2:30 p.m. June 3, Dr. Steve Given, the Dean ... he will discuss the new First Professional Doctorate program. ...
(Date:5/22/2015)... Omar Ahmad Barrada, a junior at Milton Hershey ... Congress of Future Medical Leaders in Boston, Mass. The ... highest achieving high school students.” , “I’m excited to ... and learn better study habits,” said Omar. “The event ... can ask the surgeons questions.” , The goal is ...
(Date:5/22/2015)... May 22, 2015 Carnegie Science ... today announced a new partnership to develop BodyTech, a ... region. The initiative includes a new exhibit at the ... demonstration theater, and a new traveling science show, Anatomy ... of 2015. , Designed to explore a wide ...
(Date:5/22/2015)... MOUNTAIN VIEW, California (PRWEB) May 22, 2015 ... Breakers, has set a RecordSetter.com World Record at the 104th ... Coco Libre coconut water ice luge served 315 people in ... Zappos.com Bay to Breakers race is so true to the ... that we felt bringing an ice luge to the finish ...
(Date:5/22/2015)... New York, NY (PRWEB) May 22, 2015 ... abstract entitled “Positivity Rates and Genotype Results in ‘Baby ... Action: Results from a Nationwide Lab Test Database” at Digestive ... conducted by Medivo’s Clinical Affairs and Analytics team members Carol ... Dhaliwal, MD; and Andrea Parker, MSI, along with Nancy Reau, ...
Breaking Medicine News(10 mins):Health News:ACTCM Announces Upcoming June Events 2Health News:Milton Hershey School Student Chosen for Congress of Future Medical Leaders 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 4Health News:Coco Libre Ice Luge Sets New World Record at Bay to Breakers 2Health News:Medivo Study Finds HCV Positivity Rates are 250% Higher Among Baby Boomers 2
... know answers to everything. This gains special// importance when we ... we questioned the diseases that make our precious body their ... a breakthrough have unraveled the mystery surrounding heart failure. They ... heart uses too much fatty acid and not enough carbohydrate; ...
... findings of a recent study researchers say Cocoa flavonols, ... on the brain. Cocoa flavonols were found to increase blood ... a study on 16 healthy young women, researcher tested the ... were asked to consume a flavonol-rich CocoaVia drink made by ...
... a key gene that controls specialized brain cells// is ... to better treatment of conditions ranging from schizophrenia to ... University of Singapore (NUS) study has unveiled a new ... protective fatty nerve coverings. Named juxtanodin, the gene speeds ...
... with an asthmatic attack// in children can go a long ... from asthma., ,Asthma is a leading cause of death ... is one of the leading causes of hospitalization in school-age ... day in school, experts say it is imperative that everyone ...
... responsible for post-traumatic nightmares according// to a new research. ... recognized condition that results in unpleasant memories that can ... researchers have discovered what causes this following experiments on ... event are remembered longer by a person than a ...
... hearing loss in people apart// from the all other ... The researches are featured in the July edition of ... researchers have found a previously unreported hereditary syndrome composed ... due to a lesion of the auditory division of ...
Cached Medicine News:Health News:Knowledge Of Asthma For Teachers Can Help Children 2Health News:Research Finds How Post-traumatic Stress Leads to Long-Lasting Memories 2Health News:Research Finds How Post-traumatic Stress Leads to Long-Lasting Memories 3Health News:Studies On Hearing Loss Discovers New Causes 2
... the essence of what Siemens represents: innovative ... compact size that offers enhanced solutions that ... and cost-conscious investor. Available in 2-slice, ... able to perform routine and advanced applications ...
... highly respected single-source CT solution, from imaging ... With its proprietary STRATON X-ray tube, Siemens ... 0.33s, virtually freezing the hearts motion. Utilizing ... unprecedented diagnostic detail with up to 64 ...
... Bravo is a SmartBeam platform providing high-performance scanning ... two most vital clinical sites - spine and ... dose., ,The full-function DPX Bravo densitometer gives you ... footprint. You can place it in almost any ...
... Pachmate (DGH 55) is the ultimate in portable ... ounces in weight. The Pachmate is a handheld ... The Pachmate will easily fit in a ... is rugged in design and one of the ...
Medicine Products: